CO5300398A1 - METHOD FOR THE TREATMENT OF CHRONIC PAIN THROUGH THE USE OF MEK INHIBITORS - Google Patents

METHOD FOR THE TREATMENT OF CHRONIC PAIN THROUGH THE USE OF MEK INHIBITORS

Info

Publication number
CO5300398A1
CO5300398A1 CO00053304A CO00053304A CO5300398A1 CO 5300398 A1 CO5300398 A1 CO 5300398A1 CO 00053304 A CO00053304 A CO 00053304A CO 00053304 A CO00053304 A CO 00053304A CO 5300398 A1 CO5300398 A1 CO 5300398A1
Authority
CO
Colombia
Prior art keywords
alkyl
cycloalkyl
hydrogen
optionally contains
hydroxy
Prior art date
Application number
CO00053304A
Other languages
Spanish (es)
Inventor
Alistair Dixon
Kevin Lee
Robert Denham Pinnock
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CO5300398A1 publication Critical patent/CO5300398A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Abstract

Un método para tratar el dolor crónico, dicho método comprende administrar a un individuo que necesita dicho tratamiento una composición que comprende un inhibidor MEK seleccionado de un compuesto que se define en la Fórmula I<EMI FILE="00053304_1" ID="1" IMF=JPEG >donde:R1 es hidrógeno, hidroxi, alquilo de C1-C8, alcoxi de C1-C8, halo, trifluorometilo, o CN;R2 es hidrógeno;R3, R4, y R5 son independientemente hidrógeno, hidroxi, halo, trifluorometilo, alquilo de C1-C8, alcoxi de C1-C8, nitro, CN, o (O o NH)m -(CH2)n-R9, donde R9 es hidrógeno, hidroxi, CO2H, o NR10R11;n es 0-4;m es 0 ó 1;R10 y R11 son independientemente hidrógeno o alquilo de C1-C8, o tomados juntos con el nitrógeno al que están unidos pueden completar un anillo cíclico de 3-10 miembros que opcionalmente contienen 1, 2, o 3 heteroátomos adicionales seleccionados de O, S, NH, o alquilo de N-C1-C8; O ||R6 es hidrógeno, alquilo de C1-C8, alquilo de C -C1-C8 arilo, aralquilo o cicloalquilo de C3-C10;R7 es hidrógeno, alquilo de C1-C8, alquenilo de C2-C8, alquinilo de C2-C8, cicloalquilo de C3-C10, (cicloalquilo o cicloalquilo que opcionalmente contiene un heteroátomo seleccionado de O, S, o NR9);y donde cualquiera de los grupos alquilo, alquenilo, y alquinilo que anteceden pueden ser no sustituidos o sustituidos por cicloalquilo (o cicloalquilo que opcionalmente contiene un heteroátomo seleccionado de O, S, o NR9), arilo, ariloxi, heteroarilo, o heteroariloxi; o R6 y R7 tomados juntos con el N-O al que están unidos pueden completar un anillo cíclico de 5 a 10 miembros, que opcionalmente contiene uno, dos o tres heteroátomos adicionales seleccionados de O, S, o NR10R11.A method for treating chronic pain, said method comprises administering to an individual in need of said treatment a composition comprising a MEK inhibitor selected from a compound defined in Formula I <EMI FILE = "00053304_1" ID = "1" IMF = JPEG> where: R1 is hydrogen, hydroxy, C1-C8 alkyl, C1-C8 alkoxy, halo, trifluoromethyl, or CN; R2 is hydrogen; R3, R4, and R5 are independently hydrogen, hydroxy, halo, trifluoromethyl, C1-C8 alkyl, C1-C8 alkoxy, nitro, CN, or (O or NH) m - (CH2) n-R9, where R9 is hydrogen, hydroxy, CO2H, or NR10R11; n is 0-4; m is 0 or 1; R10 and R11 are independently hydrogen or C1-C8 alkyl, or taken together with the nitrogen to which they are attached can complete a 3-10 membered cyclic ring that optionally contains 1, 2, or 3 additional heteroatoms selected of O, S, NH, or N-C1-C8 alkyl; O || R6 is hydrogen, C1-C8 alkyl, C-C1-C8 aryl alkyl, aralkyl or C3-C10 cycloalkyl; R7 is hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2- alkynyl C8, C3-C10 cycloalkyl, (cycloalkyl or cycloalkyl which optionally contains a heteroatom selected from O, S, or NR9); and where any of the above alkyl, alkenyl, and alkynyl groups may be unsubstituted or substituted by cycloalkyl ( or cycloalkyl which optionally contains a heteroatom selected from O, S, or NR9), aryl, aryloxy, heteroaryl, or heteroaryloxy; or R6 and R7 taken together with the N-O to which they are attached can complete a 5 to 10 membered cyclic ring, which optionally contains one, two or three additional heteroatoms selected from O, S, or NR10R11.

CO00053304A 1999-07-16 2000-07-14 METHOD FOR THE TREATMENT OF CHRONIC PAIN THROUGH THE USE OF MEK INHIBITORS CO5300398A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14429299P 1999-07-16 1999-07-16

Publications (1)

Publication Number Publication Date
CO5300398A1 true CO5300398A1 (en) 2003-07-31

Family

ID=22507940

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00053304A CO5300398A1 (en) 1999-07-16 2000-07-14 METHOD FOR THE TREATMENT OF CHRONIC PAIN THROUGH THE USE OF MEK INHIBITORS

Country Status (16)

Country Link
EP (1) EP1202726A2 (en)
JP (1) JP2003504400A (en)
KR (1) KR20020012315A (en)
CN (1) CN1373660A (en)
AR (1) AR024732A1 (en)
AU (1) AU5786000A (en)
CA (1) CA2374052A1 (en)
CO (1) CO5300398A1 (en)
HU (1) HUP0202623A3 (en)
IL (1) IL147619A0 (en)
NZ (1) NZ515567A (en)
PE (1) PE20010545A1 (en)
PL (1) PL352684A1 (en)
TR (1) TR200200082T2 (en)
WO (1) WO2001005392A2 (en)
ZA (1) ZA200109907B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3401A1 (en) 2000-07-19 2002-01-24 Warner Lambert Co OXYGEN ESTERS OF 4-IODOPHENYLAMINO BENZHYDROXAMIC ACIDS
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
SI1482932T1 (en) 2002-03-13 2010-02-26 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
ES2331246T3 (en) 2003-07-24 2009-12-28 Warner-Lambert Company Llc DERIVATIVES OF BENZAMIDAZOL AS INHIBITORS OF THE MEK.
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1676837A4 (en) * 2003-10-08 2008-09-10 Teijin Pharma Ltd Process for producing aminopyrrolidine derivative and intermediate compound
RU2352558C2 (en) 2003-10-21 2009-04-20 Уорнер-Ламберт Компани Ллс Polymorphic form of n-[(r)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AU2004293436B2 (en) 2003-11-19 2010-12-09 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CN1882347A (en) 2003-11-21 2006-12-20 阿雷生物药品公司 AKT protein kinase inhibitors
TWI361066B (en) * 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
DK1922307T3 (en) 2005-05-18 2012-04-02 Array Biopharma Inc Heterocyclic Inhibitors of MEK and Methods for Using Them
CA3052368A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9303040B2 (en) 2006-07-06 2016-04-05 Array Biopharma Inc. Substituted piperazines as AKT inhibitors
CA2656618C (en) 2006-07-06 2014-08-26 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
JP5231410B2 (en) 2006-07-06 2013-07-10 アレイ バイオファーマ、インコーポレイテッド Dihydrofuropyrimidine as an AKT protein kinase inhibitor
CN105106199A (en) 2006-12-14 2015-12-02 埃克塞利希斯股份有限公司 Methods of using MEK inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2173723B3 (en) 2007-07-05 2014-11-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
TWI450720B (en) 2007-07-05 2014-09-01 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CN101868443A (en) 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-phenyl anthranilic acid derivatives and uses thereof
US8198279B2 (en) 2007-12-19 2012-06-12 Institute Of Cancer Research: Royal Cancer Hospital (The) Pyrido[2,3-b]pyrazin-8-substituted compounds and their use
EP2247578B1 (en) 2008-01-09 2013-05-22 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
JP5539225B2 (en) 2008-01-09 2014-07-02 アレイ バイオファーマ、インコーポレイテッド Hydroxylated pyrimidylcyclopentane as an AKT protein kinase inhibitor
EP2346818B1 (en) 2008-11-10 2012-12-05 Bayer Intellectual Property GmbH Substituted sulphonamido phenoxybenzamides
CN102574782B (en) 2009-10-21 2014-10-08 拜耳知识产权有限责任公司 Substituted halophenoxybenzamide derivatives
WO2011047795A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
AU2011209586B2 (en) 2010-02-01 2016-01-21 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro- 4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo [4,5-b]pyridin-7-yloxy)-phenyl] -urea and related compounds and their use in therapy
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
RS56759B1 (en) 2011-04-01 2018-04-30 Genentech Inc Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
EP2694073B1 (en) 2011-04-01 2018-08-08 Genentech, Inc. Combinations of akt and mek inhibitors for treating cancer
MY186549A (en) 2012-10-12 2021-07-26 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
AU2014318748B2 (en) 2013-09-11 2019-02-28 Duquesne University Of The Holy Ghost Novel anthranilic amides and the use thereof
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3368026A1 (en) * 2015-10-27 2018-09-05 Acetylon Pharmaceuticals, Inc. Hdac inhibitors for the treatment of diabetic peripheral neuropathy
AU2018351475A1 (en) 2017-10-17 2020-04-30 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
WO2020259787A1 (en) * 2019-06-28 2020-12-30 University Of Copenhagen Treatment of cns disorders with sleep disturbances

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
EP0993439B1 (en) * 1997-07-01 2004-09-29 Warner-Lambert Company LLC 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
WO1999001421A1 (en) * 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
CA2346448A1 (en) * 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors

Also Published As

Publication number Publication date
NZ515567A (en) 2004-03-26
TR200200082T2 (en) 2002-04-22
ZA200109907B (en) 2003-02-28
AU5786000A (en) 2001-02-05
WO2001005392A3 (en) 2001-07-19
JP2003504400A (en) 2003-02-04
KR20020012315A (en) 2002-02-15
PL352684A1 (en) 2003-09-08
EP1202726A2 (en) 2002-05-08
CN1373660A (en) 2002-10-09
PE20010545A1 (en) 2001-06-04
WO2001005392A2 (en) 2001-01-25
IL147619A0 (en) 2002-08-14
CA2374052A1 (en) 2001-01-25
HUP0202623A3 (en) 2003-03-28
HUP0202623A2 (en) 2002-11-28
AR024732A1 (en) 2002-10-23

Similar Documents

Publication Publication Date Title
CO5300398A1 (en) METHOD FOR THE TREATMENT OF CHRONIC PAIN THROUGH THE USE OF MEK INHIBITORS
CO5150150A1 (en) 4-OXO-1,4-DIHIDRO-3-QUINOLEINCARBOXAMIDAS AS ANTIVIRAL AGENTS
EA200401284A1 (en) SUBSTITUTED BENZEZOLES AND THEIR APPLICATION AS RAF KINASE INHIBITORS AS AN INHIBITORS
AR016762A1 (en) 4-BROMO OR 4-IODINE PHENYLAMINE BENZOHIDROXAMIC ACID COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USE OF THE SAME
PE20020585A1 (en) METALOPROTEINASE INHIBITORS OF THE TYPE PYRIMIDIN-2,4,6-TRIONA
FI972628A0 (en) New sulfonamides
DE69523169T2 (en) Use of mangiferin or its derivatives for cosmetic use
EA200300323A1 (en) DERIVATIVES OF GUANIDININOBENZAMIDE (OPTIONS), COMPOSITION (OPTIONS), METHOD OF TREATMENT OF MEDIATED DISTRIBUTIONS mc4-r
FI964772A (en) (a) annealed pyrrole derivatives and their use in pharmacin
CO5251467A1 (en) PIPERAZINE DERIVATIVES
BR9608048A (en) Benzimidazole compounds, pharmaceutical compositions containing the compounds and their use.
EA199800909A1 (en) MESILATE TRIGHYDRATE 5- (2- (4- (1,2-BENZIZOTIAZOL-3-IL) PIPERAZIN-1-IL) ETHIL) -6-CHLOR-1,3-DIHYDRO-2H-INDOL-2-IT, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT OF MENTAL DISORDER
CO5060482A1 (en) BIARILO THERAPEUTIC DERIVATIVES
ATE402701T1 (en) N-(8,8,8-TRIFLUOROOCTYL)-1,5-DIDEOXY-1,5-IMINO- - GLUCITOL FOR THE TREATMENT OF HEPATITIS VIRUS INFECTIONS
EA201001081A1 (en) TETRACYCLINE COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF TETRACYCLINE-SENSITIVE CONDITION IN THE SUBJECT
CO5251464A1 (en) INHIBITORS OF N- (5 - (((5-RENT-2-OXAZOLIL) METHYL) UNCLE) -2- TIAZOLIL) -CARBOXAMIDE OF CYCLINE DEPENDENT KINASES
AR031597A1 (en) PIPERIDINE COMPOUNDS, A PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITIONS, AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR USE AS CCR-3 INHIBITORS
BR9307580A (en) Process compounds for the preparation of the same pharmaceutical compositions use of a compound and process for the treatment of a mammal that includes humans
TR199701219T1 (en) Benzimidazole compounds, these compounds are Spanish compounds.
CO5180605A1 (en) INDOL COMPOUNDS
DE60105025D1 (en) PHARMACEUTICAL COMPOUNDS FOR TREATING CHRONIC-OBSTRUCTIVE BRONCHOPNEUMONIA
ES2119094T3 (en) INHIBITION OF DYSFUNCTIONAL UTERINE HEMORRHAGE.
DK0920426T3 (en) Novel thiazole derivatives with phosphodiesterase inhibitory effect
EA200200596A1 (en) OX (ADI) AZOLYL HYDROXAMIC ACIDS, USEFUL AS PROGOLAGEN-C-PROTEINASE AS USE AS INHIBITORS
CO5080801A1 (en) PROTEASE INHIBITORS

Legal Events

Date Code Title Description
FC Application refused